Akebia Therapeutics Inc. buy BTIG Research
Start price
29.11.23
/
50%
€0.92
Target price
29.11.24
€3.64
Performance (%)
28.20%
Price
23.09.24
€1.18
Summary
This prediction is currently active. The prediction currently has a performance of 28.20%. This prediction currently runs until 29.11.24. The prediction end date can be changed by BTIG_Research at any time. BTIG_Research has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m |
---|---|---|
Akebia Therapeutics Inc. | - | - |
iShares Core DAX® | -1.114% | 5.062% |
iShares Nasdaq 100 | 1.816% | 9.828% |
iShares Nikkei 225® | 2.113% | 8.218% |
iShares S&P 500 | 2.038% | 7.448% |
Comments by BTIG_Research for this prediction
In the thread Akebia Therapeutics Inc. diskutieren
Akebia Therapeutics, Inc. (NASDAQ: AKBA) had its "buy" rating re-affirmed by analysts at BTIG Research. They now have a $4.00 price target on the stock.
Ratings data for AKBA provided by MarketBeat